Table 1. Baseline, clinical and laboratories characteristics of study patients.

Variable	Total (N = 326)	Severe dengue (N = 99)	Non severe dengue (N = 227)
	n (%)	n (%)	n (%)
Baseline characteristics
Gender
• Male	166 (50,9)	51 (51.5)	115 (50.7)
• Female	160 (49,1)	48 (48.5)	112 (49.3)
Age
• 6–10 years	32 (9.8)	10 (10.1)	9.7)
• 11–20 years	112 (34.4)	26 (26.3)	37.9)
• 21–30 years	89 (27.3)	37 (37.4)	22.9)
• 31–40 years	44 (13.5)	8 (8.1)	15.9)
• 41–50 years	32 (9.8)	12 (12.1)	8.8)
• ≥ 51 years	17 (5.2)	6 (6.1)	11 (4.8)
Underlying disease
• Yes	40 (12.3)	11 (11.1)	12.8)
• No	286 (87.7)	88 (88.9)	198 (87.2)
Clinical manifestations
Fever	326 (100.0)	99 (100.0)	227 (100.0)
Skin rash	251 (77.0)	65 (65.7)	186 (81.9)
Myalgia	215 (66.0)	60 (60.6)	155 (68.3)
Haemorrhagic manifestations	190 (58.3)	56 (56.6)	9.0)
• Petechiae	106 (32.5)	32 (32.3)	32.6)
• Mucosal bleeding	149 (45.7)	41 (41.4)	108 (47.6)
Vomiting and /or nausea	159 (48.8)	39 (39.4)	120 (52.9)
Abdominal pain	113 (34.7)	36 (36.4)	77 (33.9)
Loose stools	54 (16.6)	14 (14.1)	40 (17.6)
Hepatomegaly	13 (4.0)	7 (7.1)	6 (2.6)
Peripheral blood
• Hematocrit > 0.4 l/L	208 (63.8)	78 (78.8)	9.9)
• WBC < 5 G/L	257 (78.8)	72 (72.7)	1.5)
• Platelets ≤ 100 G/L	213 (65.3)	79 (79.8)	134 (59.0)
Biochemical parameters
Creatinin > 120 μmol/L	30 (9.2)	30 (30.3)	0 (0.0)
Liver enzymes
• AST > 40 U/L	269 (82.5)	87 (87.9)	182 (80.2)
• ALT > 40 U/L	210 (64.4)	81 (81.8)	129 (56.8)
Albumin < 35 g/L	57 (17.5)	32 (32.3)	25/226 (11.1)
Bilirubin TT > 17 μmol/L	39 (12.0)	27 (27.3)	12 (5.3)
Glucose
• ≤ 3.9 mmol/L	6 (1.9)	3/98 (3.1)	3 (1.3)
• ≥ 6.4 mmol/L	2 (0.6)	0 (0.0)	2/225 (0.9)
Coagulation parameters
• PT < 70%	26 (8.0)	13 (13.1)	13 (5.7)
• PTs > 13 (s)	90 (27.6)	40 (40.4)	50 (22.0)
• Fibrinogen < 2 g/L	90 (27.9)	42 (42.4)	48 (21.1)
• aPTT > 40 (s)	163 (50.0)	49 (49.5)	114 (50.2)
• INR > 1.25 (s)	28 (8.6)	11 (11.1)	17 (7.5)
DENV type
• DEN-1	316 (96.9)	94 (94.9)	222 (97.8)
• DEN-2	10 (3.1)	5 (5.1)	5 (2.2)